Rubius Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and immunotherapies to treat immune-mediated diseases, with a focus on B-cell targeting approaches. The company's lead program is budoprutug, an anti-CD19 antibody designed to deplete B cells in patients with primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, while a second program, CLYM116, targets APRIL for IgA nephropathy and other B-cell disorders. Rubius generates no current revenue as a pre-commercial clinical-stage company but advances its pipeline through partnerships with manufacturers and licensors, with the goal of eventually commercializing therapeutics that address the large patient populations in immune-mediated disease markets.